Literature DB >> 11159158

Impact of estrogen use on decline in cognitive function in a representative sample of older community-resident women.

G G Fillenbaum1, J T Hanlon, L R Landerman, K E Schmader.   

Abstract

The authors investigated whether postmenopausal estrogen use helps to maintain cognitive function; a brief screen, the Short Portable Mental Status Questionnaire (SPMSQ), was used. Information was gathered from a stratified, random sample of 1,907 African-American and White women (aged 65-100 years) participating in the longitudinal Duke Established Populations for Epidemiologic Studies of the Elderly project carried out in five urban and rural counties of North Carolina. All women were cognitively unimpaired in 1986-1987 and were evaluated 3 and 6 years later. Decline in cognitive function was measured as an increase of two or more errors on the SPMSQ and crossing of an SPMSQ threshold indicative of cognitive impairment. Recency and continuity of estrogen use were measured. Univariate analyses indicated that recent (crude odds ratio = 0.42, 95% confidence interval: 0.21, 0.86) and continuous (crude odds ratio = 0.32, 95% confidence interval: 0.13, 0.81) estrogen use reduced the risk of cognitive decline but not of cognitive impairment. After adjustment for demographic and health characteristics, protective effects became nonsignificant. While postmenopausal use of estrogen may be protective for Alzheimer's disease, current findings based on a brief cognitive screen suggest that it is not protective for cognitive decline related to aging.

Entities:  

Mesh:

Year:  2001        PMID: 11159158     DOI: 10.1093/aje/153.2.137

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  7 in total

1.  Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline.

Authors:  Jae H Kang; Francine Grodstein
Journal:  Neurobiol Aging       Date:  2010-11-30       Impact factor: 4.673

Review 2.  The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review.

Authors:  Ronald F Zec; Mehul A Trivedi
Journal:  Neuropsychol Rev       Date:  2002-06       Impact factor: 7.444

3.  Evaluation of prefrontal-hippocampal effective connectivity following 24 hours of estrogen infusion: an FDG-PET study.

Authors:  William E Ottowitz; Karen L Siedlecki; Martin A Lindquist; Darin D Dougherty; Alan J Fischman; Janet E Hall
Journal:  Psychoneuroendocrinology       Date:  2008-10-31       Impact factor: 4.905

4.  Therapeutic approaches to age-associated neurocognitive disorders.

Authors:  R O'Hara; C Derouesné; K N Fountoulakis; J A Yesavage
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

5.  Comparative analysis of cognitive impairment prevalence and its etiological subtypes in a rural area of northern China between 2010 and 2015.

Authors:  Hui Lu; Xiao-Dan Wang; Zhihong Shi; Wei Yue; Ying Zhang; Shuai Liu; Shuling Liu; Lei Zhao; Lei Xiang; Yajing Zhang; Yalin Guan; Wenhua Su; Zhiyong Li; Jinhuan Wang; Thomas Wisniewski; Yong Ji
Journal:  Sci Rep       Date:  2019-01-29       Impact factor: 4.379

6.  Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause.

Authors:  Virginia M Miller; Vesna D Garovic; Kejal Kantarci; Jill N Barnes; Muthuvel Jayachandran; Michelle M Mielke; Michael J Joyner; Lynne T Shuster; Walter A Rocca
Journal:  Biol Sex Differ       Date:  2013-03-28       Impact factor: 5.027

7.  Dementia / Alzheimer's Disease.

Authors:  Joan Lindsay; Lori Anderson
Journal:  BMC Womens Health       Date:  2004-08-25       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.